Back

Targeting the histone methyltransferase SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Epigenetic targets in cardiovascular disease Microcirculation, Angiogenesis, Arteriogenesis ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Shafeeq Ahmed Mohammed

University Hospital Zurich, Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail
Targeting BRD4-HK2 reverses the meta-inflammatory shift in perivascular adipose tissue and rescues cardiometabolic vascular dysfunction.
Assistant Professor A. Mengozzi (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Chromatin remodeling by the histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction
Doctor S. Costantino (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial
Doctor E. Kulikowski (Calgary, CA)
Abstract Slides Video
Presentation thumbnail
The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation
Doctor E. Gorica (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
RBM20 promotes doxorubicin-induced cardiotoxicity by Atp6v0a1 alternative splicing
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Epigenetic targets in cardiovascular disease
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources